US biopharmaceutical company NanoBio Corporation has changed its name to BlueWillow Biologics, which the company says “reflects its evolution to a vaccines-focused company, and commitment to advancing its novel intranasal technology to develop new vaccines for several respiratory and sexually transmitted diseases.” The company also announced the closing of a $10 million Series A financing to fund development of those vaccines.
BlueWillow’s intranasal vaccine platform uses its NanoVax nanoemulsion adjuvant. The company’s pipeline includes vaccines for anthrax, chlamidia, herpes simplex virus 2 (HSV-2), influenza, pertussis, and respiratory syncytial virus (RSV).
BlueWillow CEO Dave Peralta commented, “Over the past several years, our research has increasingly demonstrated that our intranasal platform can play a pivotal role in the vaccines of tomorrow. Much of our data points to increased protection against some of the world’s most severe respiratory and sexually transmitted infections. With the commitment of our Series A investors and the tremendous support we continue to receive from the National Institutes of Health (NIH), BlueWillow is now rapidly approaching Phase 1 human clinical studies in several programs.”
Peralta added, “The NIH, Bill & Melinda Gates Foundation, State of Michigan, Michigan Nanotechnology Institute for Medicine and Biological Sciences and the University of Michigan Technology Transfer Office have been instrumental in the advancement of BlueWillow’s intranasal vaccine platform. We are very grateful to each of these partners, as well as our core investors, for their support, guidance and investment in BlueWillow’s promising future.”
Read the BlueWillow Biologics press release.
